LifeVantage (LFVN)
Provides nutrigenomic wellness products to customers and independent consultants.
$6.05
vs last close−0.17 (−2.73%)
In millions of USD, except per-share figures
| In millions | Q1 FY24Sep 2023 | Q2 FY24Dec 2023 | Q3 FY24Mar 2024 | Q4 FY24Jun 2024 | Q1 FY25Sep 2024 | Q2 FY25Dec 2024 | Q3 FY25Mar 2025 | Q4 FY25Jun 2025 | Q1 FY26Sep 2025 | Q2 FY26Dec 2025 | Q3 FY26Mar 2026 | Q4 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51 | 52 | 48 | 49 | 47 | 68 | 58 | 55 | 48 | 49 | 44 | 42 |
| Cost of revenue | 10 | 11 | 10 | 10 | 9 | 13 | 11 | 11 | 10 | 13 | 9 | 9 |
| Gross profit | 41 | 41 | 38 | 39 | 38 | 55 | 47 | 44 | 38 | 36 | 35 | 33 |
| 40 | 42 | 36 | 36 | 35 | 51 | 43 | 42 | 36 | 36 | 33 | 31 | |
| Research & development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 40 | 42 | 36 | 14 | 15 | 19 | 17 | 19 | 36 | 16 | 14 | 70 | |
| Selling & marketing | 22 | 22 | 20 | 0 | 0 | 0 | 0 | 0 | 21 | 0 | 0 | 56 |
| General & administrative | 18 | 20 | 16 | 14 | 15 | 19 | 17 | 19 | 15 | 16 | 14 | 14 |
| Other expenses | 0 | 0 | 0 | 22 | 20 | 33 | 26 | 23 | 0 | 20 | 19 | −39 |
| Operating income | 1 | −1 | 2 | 3 | 3 | 3 | 4 | 2 | 2 | 0 | 2 | 2 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | 1 | −1 | 2 | 3 | 3 | 3 | 4 | 2 | 2 | 0 | 2 | 2 |
| Income tax expense | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 1 | −1 | 2 | 1 | 2 | 3 | 3 | 2 | 2 | 0 | 1 | 1 |
| Net income | 1 | −1 | 2 | 1 | 2 | 3 | 3 | 2 | 2 | 0 | 1 | 1 |
| EPS, basic | $0.05 | −$0.05 | $0.13 | $0.11 | $0.15 | $0.21 | $0.28 | $0.16 | $0.17 | $0.02 | $0.11 | $0.10 |
| EPS, diluted | $0.05 | −$0.05 | $0.13 | $0.10 | $0.14 | $0.19 | $0.26 | $0.15 | $0.17 | $0.02 | $0.11 | $0.10 |
| Weighted average shares, basic | 13 | 13 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 13 | 13 | 13 |
| Weighted average shares, diluted | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| EBITDA | 2 | 0 | 3 | 4 | 3 | 4 | 5 | 3 | 3 | 1 | 2 | 2 |
| Depreciation & amortization | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBIT | 1 | −1 | 2 | 3 | 3 | 3 | 4 | 2 | 2 | 0 | 2 | 2 |